

PRESS RELEASE
2013 first-quarter revenue

Villepinte, 23 April 2013

Consolidated Group revenue (IFRS)

In € thousands	2012	2013	Change
Total first quarter.....	96,758	90,995	- 6.0%

Consolidated revenue by region

In € thousands	2012	2013	Change
Sales in Europe	70,617	65,383	- 7.4%
Sales in other markets	26,141	25,612	- 2.0%
Total.....	96,758	90,995	- 6.0%

Year's start impacted by the good performance in 2012 H2

Growth in the 2012 second half (+10.9%) that was driven mainly by exceptional sales due to the X-Ray line in Europe slowed momentum for the start of 2013, resulted in a lag in sales of 6% in relation to the first quarter of 2012.

The MRI line contracted 1.3%, notably in response to a decline in reimbursement rates in Switzerland, Belgium and South Korea.

X-Ray product sales were also down (-14.6%), particularly in Europe for the reasons cited above.

Other products in contrast achieved significant gains of 19.3% and in large part attributable to Lipiodol.

Sales trends in the first quarter do not affect the guidance for annual growth of 3% announced at the start of the year.

Contact: CFO Department - Tel.: +33 (0)1 45 91 50 69